Do different treatment strategies of galcanezumab have a similar effect on migraine?

Abstract

We read with interest a report of pooled analysis of EVOLVE trials for revealing the efficacy of galcanezumab on migraine patients with history of preventive treatment failure on European journal of neurology in November 2019 [1]. The report evaluated effects of galcanezumab 120mg (GMB120) and 240mg (GMB240) in migraine patients with 0 prior preventives, ≥1 prior preventive failure, and ≥2 prior preventive failure, and the authors concluded that Galcanezumab with its mechanism of action targeting the pathophysiology of migraine, and favourable efficacy may offer an effective treatment option for patients with episodic migraine who have failed prior preventives. It still needs to be clarified which treatment strategy of galcanezumab may be the most effective in treating migraine patients with history of preventive treatment failure though there were many studies on this topic [2-8].